Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes

被引:109
作者
Forst, T. [3 ]
Uhlig-Laske, B. [2 ]
Ring, A. [2 ]
Graefe-Mody, U. [2 ]
Friedrich, C. [2 ]
Herbach, K. [2 ]
Woerle, H. -J. [2 ]
Dugi, K. A. [1 ]
机构
[1] Boehringer Ingelheim GmbH & Co KG, Corp Dept Med Affairs, D-55216 Ingelheim, Germany
[2] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany
[3] Forsch & Entwicklung GmbH, Inst Klin, Mainz, Germany
关键词
linagliptin; metformin; safety and efficacy; DIPEPTIDYL PEPTIDASE-4 INHIBITORS; THERAPY; PHARMACOKINETICS; MELLITUS; PHARMACODYNAMICS; HYPERGLYCEMIA; TOLERABILITY; SITAGLIPTIN; DISPOSITION; SECRETION;
D O I
10.1111/j.1464-5491.2010.03131.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
P>Aims The efficacy and safety of the dipeptidyl peptidase-4 inhibitor, linagliptin, added to ongoing metformin therapy, were assessed in patients with Type 2 diabetes who had inadequate glycaemic control (HbA(1c) >= 7.5 to < 10%; >= 58.5 to < 85.8 mmol/mol) with metformin alone. Methods Patients (n = 333) were randomized to receive double-blind linagliptin (1, 5 or 10 mg once daily) or placebo or open-label glimepiride (1-3 mg once daily). The primary outcome measure was the change from baseline in HbA(1c) at week 12 in patients receiving combination therapy compared with metformin alone. Results Twelve weeks of treatment resulted in a mean (sem) placebo-corrected lowering in HbA(1c) levels of 0.40% (+/- 0.14); 4.4 mmol/mol (+/- 1.5) for 1 mg linagliptin, 0.73% (+/- 0.14); 8.0 mmol/mol (+/- 1.5) for 5 mg, and 0.67% (+/- 0.14); 7.3 mmol/mol (+/- 1.5) for 10 mg. Differences between linagliptin and placebo were statistically significant for all doses (1 mg, P = 0.01; 5 mg and 10 mg, P < 0.0001). The change in mean (sem) placebo-corrected HbA(1c) from baseline was -0.90% (+/- 0.13); -9.8 mmol/mol (+/- 1.4) for glimepiride. Adjusted and placebo-corrected mean changes in fasting plasma glucose were -1.1 mmol/l for linagliptin 1 mg (P = 0.002), -1.9 mmol/l for 5 mg and -1.6 mmol/l for 10 mg (both P < 0.0001). One hundred and six (43.1%) patients reported adverse events; the incidence was similar across all five groups. There were no hypoglycaemic events for linagliptin or placebo, whereas three patients (5%) receiving glimepiride experienced hypoglycaemia. Conclusions The addition of linagliptin to ongoing metformin treatment in patients with Type 2 diabetes was well tolerated and resulted in significant and clinically relevant improvements in glycaemic control, with 5 mg linagliptin being the most effective dose.
引用
收藏
页码:1409 / 1419
页数:11
相关论文
共 31 条
[1]   Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetes [J].
Ahren, Bo .
EXPERT OPINION ON EMERGING DRUGS, 2008, 13 (04) :593-607
[2]   Drug therapy - Metformin [J].
Bailey, CJ ;
Turner, RC .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (09) :574-579
[3]   The Metabolism and Disposition of the Oral Dipeptidyl Peptidase-4 Inhibitor, Linagliptin, in Humans [J].
Blech, Stefan ;
Ludwig-Schwellinger, Eva ;
Graefe-Mody, Eva Ulrike ;
Withopf, Barbara ;
Wagner, Klaus .
DRUG METABOLISM AND DISPOSITION, 2010, 38 (04) :667-678
[4]   Lower baseline glycemia reduces apparent oral agent glucose-lowering efficacy - A meta-regression analysis [J].
Bloomgarden, Zachary T. ;
Dodis, Regina ;
Viscoli, Catherine M. ;
Holmboe, Eric S. ;
Inzucchi, Silvio E. .
DIABETES CARE, 2006, 29 (09) :2137-2139
[5]   Rationale for dipeptidyl peptidase 4 inhibitors: A new class of oral agents for the treatment of type 2 diabetes mellitus [J].
Campbell, R. Keith .
ANNALS OF PHARMACOTHERAPY, 2007, 41 (01) :51-60
[6]   Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes [J].
Deacon, Carolyn F. ;
Holst, Jens J. .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2010, 19 (01) :133-140
[7]   Inhibitors of dipeptidyl peptidase IV:: a novel approach for the prevention and treatment of Type 2 diabetes? [J].
Deacon, CF ;
Ahrén, B ;
Holst, JJ .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2004, 13 (09) :1091-1102
[8]   EFFICACY OF METFORMIN IN PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES-MELLITUS [J].
DEFRONZO, RA ;
GOODMAN, AM ;
ABELOVE, W ;
REID, E ;
PITA, J ;
CALLAHAN, M ;
JOHNSON, D ;
PELAYO, E ;
PUGH, J ;
SHANK, M ;
GARZA, P ;
HAAG, B ;
KORFF, J ;
ANGELO, A ;
IZENSTEIN, B ;
VANDERLEEDEN, M ;
CATHCART, H ;
TIERNEY, M ;
BIGGS, D ;
KARAM, J ;
NOLTE, M ;
GAVIN, L ;
ELDER, MA ;
CORBOY, J ;
THWAITE, D ;
WONG, S ;
DAVIDSON, M ;
PETERS, A ;
DUNCAN, T ;
KERCHER, S ;
FISCHER, J ;
KIPNES, M ;
RADNICK, BJ ;
ROURA, M ;
ROQUE, J ;
MONTGOMERY, C ;
COLLUM, P ;
RUST, M ;
POHL, S ;
PFEIFER, M ;
ALLWEISS, P ;
LEICHTER, S ;
LEACH, P ;
GALLINA, D ;
MUSEY, V ;
BERKOWITZ, K ;
EASTMAN, R ;
TAYLOR, T ;
DELAPENA, MS ;
ZAWADSKI, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (09) :541-549
[9]   Pathogenesis of type 2 diabetes mellitus [J].
DeFronzo, RA .
MEDICAL CLINICS OF NORTH AMERICA, 2004, 88 (04) :787-+
[10]   Enhancing incretin action for the treatment of type 2 diabetes [J].
Drucker, DJ .
DIABETES CARE, 2003, 26 (10) :2929-2940